Happy to share new paper highlighting mitazalimabs role in degrading storms and enhancing T cell infiltration in PDAC tumors.
https://t.co/mnsgDpFcOJ
https://t.co/uz8JipLnWk
Happy to share our new article!
ATOR-4066, a bispecific antibody targeting CD40 and CEACAM5, induces strong myeloid and T cell–dependent tumor immunity and synergizes with PD-1 blockade https://t.co/tNPb5aJoBS
Thanks to all co-authors!
First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies https://t.co/ZL1QBfQbJG
Congratulations to #JITC Section Editor Dr. Cornelis "Kees" Melief of @UniLeidenNews for being recognized as this year's Pedro J. Romero Service to JITC Award recipient! Thank you for all of your leadership and for sharing your vision with the journal!
Prof. Leisha A. Emens MD PHD, incoming President of SITC “The Society is working to put itself out of business” curing #cancer/new VP, Dr James L. Gulley MD PHD - SITC “Family, Friends, Country” THE SOCIETY IS IN GREAT HANDS! @gulleyj1@theNCI@FDAOncology@sitcancer#SITC2022
Congratulations to this year's #JITC Best Paper Award recipients - the first authors of top original research papers from the past year! Read the papers using the QR codes and hear more about them during Session 207 in hall 205ABC! #SITC22@McAuliffe_James@ShrutiGkidney
#SITC22 Attendees: Meet #JITC Editor-in-Chief Pedro Romero and Deputy Editor-in-Chief James L Gulley today at 12:30pm EST at the SITC booth. Bring your questions!
Very proud to be part of the Alligator team behind this manuscript describing how our Neo-X-Prime technology delivers next generation CD40 targeting therapies
New #JITC article: Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies https://t.co/4280sOaGUL @EllmarkPeter
New #JITC article: Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies https://t.co/4280sOaGUL @EllmarkPeter
Scrip interviewed CEO Per Norlén last week at BIO-Europe on the company's business development strategies and development triggers. https://t.co/WY3Xf4DWf2 … …
#bioeurope#immunooncology#arevolutionforlife
Busy days for Alligator at @sitcancer in Washington DC. The three preclinical projects ATOR-1015, ATOR-1017 and ALG.APV-527 all to be showcased at the conference. #immunooncology#arevolutionforlife https://t.co/GT9LXQclJY
@AlligatorBio Vice President Discovery Peter Ellmark giving a talk in Copenhagen on the topic "Public Private Partnership in Immuno-Oncology" #IOCPH18#arevolutionforlife